Engineered NS1 for Sensitive, Specific Zika Virus Diagnosis from Patient Serology
Thai Leong Yap
1, Shin Yee Hong
1, Jun Hui Soh, Lekha Ravichandraprabhu, Vanessa W.X. Lim, Hsi-Min Chan, Tommy Z.X. Ong, Ying Ping Chua, Shi En Koh, Huajing Wang, Yee Sin Leo, Jackie Y. Ying, and William Sun
Author affiliations: Experimental Drug Development Centre, Singapore (T.L. Yap, S.Y. Hong); Institute of Bioengineering and Nanotechnology, Singapore (T.L. Yap, S.Y. Hong, L. Ravichandraprabhu, T.Z.X. Ong, Y.P. Chua, S.E. Koh, H. Wang, W. Sun); NanoBio Lab, Singapore (J.H. Soh, H.-M. Chan, J.Y. Ying); National Centre for Infectious Diseases, Singapore (V.W.X. Lim, Y.S. Leo); Tan Tock Seng Hospital, Singapore (Y.S. Leo); Yong Loo Lin School of Medicine, National University of Singapore (Y.S. Leo, W. Sun).
Main Article
Figure 6
Figure 6. Distribution of number of plasma cases (x-axes) over number of DPO (y-axes) in study of Zika diagnosis, Singapore. F1 immunochromatographic assay format tested with validation set in a blinded manner (Tan Tock Seng Hospital plasma); positive plasma (black) and total plasma cases (gray) over dpo are also shown. A, C) Zika patient samples; B, D) Dengue patient samples. dpo, days postonset of symptoms.
Main Article
Page created: April 05, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.